Skip to Content

Adlyxin Approval History

Adlyxin (lixisenatide) is a once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Adlyxin

Jul 27, 2016Approval Sanofi Receives FDA Approval of Adlyxin (lixisenatide) for Treatment of Adults With Type 2 Diabetes
Sep 29, 2015Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Sep 14, 2015Sanofi Reports Positive Top-Line Results In Second Pivotal Lixilan Phase III Study
Jun  8, 2015Sanofi's Lyxumia (lixisenatide) Demonstrated Cardiovascular Safety in People With Type 2 Diabetes and High CV Risk
Jun  6, 2015Lyxumia (Lixisenatide) Meets Co-Primary Endpoints in GetGoal Duo-2 Trial
Mar 19, 2015Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia (Lixisenatide)
Jun 14, 2014Sanofi's Lyxumia (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine
Sep 12, 2013Sanofi Provides Update on Lixisenatide New Drug Application in U.S.
Feb 19, 2013Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.